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create an imbalance in the cytokine network, 
thereby driving or unmasking previously un-
common complications. The occurrence of pul-
monary hypertension in one patient who re-
ceived canakinumab and in two who received 
tocilizumab is notable, in light of a recent re-
port of a significantly increased frequency of 
pulmonary hypertension in children with sys-
temic JIA treated with a number of different 
therapies, including anti–interleukin-1 and anti–
interleukin-6.7 To address the challenge of eval-
uating long-term and infrequent adverse events 
that occur with these therapies, new approaches 
are needed, such as consolidated disease regis-
tries designed to evaluate safety signals in the 
context of the underlying disease and exposure 
to multiple agents.
It is interesting that the participants in these 
trials had marked similarities in the magnitude 
and timing of their responses, suggesting that 
interleukin-1 and interleukin-6 may be in the 
same pathway in systemic JIA. In contrast, there 
is anecdotal evidence that some patients have a 
response to anti–interleukin-1 but not to anti–
interleukin-6, and vice versa, which is consistent 
with the complexity of proinflammatory cyto-
kine networks.8 The partial or absent responses 
in a significant minority of patients in the trials 
of both canakinumab and tocilizumab suggest 
that genetic or environmental factors may result 
in different subsets of systemic JIA. Alternative-
ly, there may be an early therapeutic window of 
opportunity during which higher response rates 
can be achieved,9 or inflammatory “escape” 
pathways may be activated because of the pres-
ence of these inhibitors. The search for the most 
proximal step that can be targeted in the in-
flammatory cascade will undoubtedly continue.
Despite important remaining questions about 
regulation of inflammation, the pathogenesis of 
systemic JIA, and appropriate interventions, 
there is no doubt that the agents tested in these 
trials signal a new era in the treatment of sys-
temic JIA and will shed light on the mecha-
nisms driving this enigmatic disorder. Contin-
ued investigation of systemic JIA is likely to 
inform our understanding of other multigenic 
autoinflammatory diseases — a growing cate-
gory that now includes type 2 diabetes and in-
flammatory bowel disease — as well as our un-
derstanding of the regulation of inflammation.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
From the Department of Pediatrics, Stanford University School 
of Medicine, Stanford, CA.
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Autosomal dominant polycystic kidney disease 
(ADPKD), the most common hereditary kidney 
disease, progresses relentlessly to end-stage kid-
ney disease before the age of 60 years in half the 
affected patients. One in 10 patients undergoing 
dialysis has ADPKD. The disease is characterized 
by prominent cystic enlargement of the kidneys, 
which is often associated with episodes of pain, 
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hematuria, and cyst infection. An effective ther-
apy to slow the progression of this disease does 
not exist, although several promising drug candi-
dates are being tested.1
Vasopressin-mediated cyclic AMP (cAMP) gen-
eration is enhanced in polycystic kidneys, driving 
the proliferation of cyst epithelial cells and the 
secretion of cyst fluid. Tolvaptan, a selective vaso-
pressin V2-receptor antagonist already in clinical 
use for the treatment of hyponatremia, decreased 
renal cAMP generation and target-gene expres-
sion in preclinical studies and was associated 
with delayed progression of ADPKD in a phase 2 
clinical study.2
In the Tolvaptan Efficacy and Safety in Man-
agement of Autosomal Dominant Polycystic Kid-
ney Disease and Its Outcomes (TEMPO) 3:4 trial, 
a large, phase 3 study now reported in the Journal, 
Torres et al. tested the efficacy and safety of 
tolvaptan in 1445 patients with ADPKD.3 At base-
line, the mean age of the participating patients 
was 39 years. Kidney function was preserved, but 
nearly 80% of the patients had hypertension. 
Kidney size was increased by a factor of five, 
and half the patients had reported kidney pain. 
The patients were randomly assigned in a 2:1 
ratio to receive two doses of tolvaptan or placebo 
daily.
The study met its primary and secondary end 
points — tolvaptan, when given at an average 
dose of 95 mg per day over a 3-year period, 
slowed the usual increase in kidney volume by 
50% and reduced the decline in the glomerular 
filtration rate (GFR). The effect of tolvaptan on 
kidney volume was most pronounced during the 
first year of the study, probably owing to the 
early reduction in the secretion of cyst fluid.4 In 
contrast, the effect on GFR became apparent 
only after the first year of treatment. A consider-
able number of patients discontinued tolvaptan 
owing to its aquaretic side effects (thirst, poly-
dipsia, polyuria, and nocturia), and tolvaptan 
treatment was also associated with elevated liver-
enzyme levels, hypernatremia, an increased level 
of uric acid, and gout. However, as compared 
with patients who received placebo, significantly 
fewer patients who received tolvaptan had ad-
verse events related to ADPKD, such as kidney 
and back pain, hematuria, and urinary tract in-
fection.
The rate of increase in kidney volume was low 
in both study groups (5.5% per year in the pla-
cebo group and 2.8% per year in the tolvaptan 
group), in contrast to growth rates of 6 to 12% 
per year in other studies.5,6 Because of the effect 
of tolvaptan on water excretion, the study design 
forced all patients to increase their fluid intake 
in order to avoid dehydration. Increased water 
intake to suppress vasopressin-mediated cAMP 
generation is recommended for patients with 
ADPKD,7 and the fact that participating patients 
followed this prescription could explain the re-
duced growth in kidney volume observed in this 
study. Nevertheless, tolvaptan, by driving fluid 
intake, slowed the expansion of cyst volume sig-
nificantly more than placebo did.
Tolvaptan was associated with a slower de-
crease in kidney function and with less pain 
than placebo was, although the number of rele-
vant events was low and contributed to less than 
20% of the secondary outcome events. The study 
did not assess the effects of tolvaptan on kidney 
pain in a systematic fashion; thus, pain data need 
to be confirmed. Furthermore, it is unclear why 
tolvaptan had no effect on worsening trajecto-
ries of hypertension and albuminuria. Assuming 
that tolvaptan causes structural rather than func-
tional improvements, one would have expected 
beneficial effects on urinary protein excretion 
and blood pressure.
Despite these criticisms, the TEMPO 3:4 study 
represents a major advancement in the quest for 
a cure for ADPKD. How might the information 
from this trial change the future care of pa-
tients with ADPKD? Would tolvaptan be a useful 
drug for the majority of such patients, or should 
it be prescribed only for those patients at great-
est risk for progression to end-stage kidney dis-
ease? As Torres et al. comment, the use of this 
V2-receptor antagonist will depend on a balance 
between benefits and risks. The side effects of 
an aquaretic drug (e.g., thirst and polyuria) will 
affect the quality of life in a substantial number 
of patients — an issue that must be weighed 
against the possible benefits of delayed dialysis 
and transplantation, decreased kidney pain, and 
fewer urinary tract infections. Some patients with 
slowly progressive disease might opt for pre-
emptive kidney transplantation (i.e., transplanta-
tion before the initiation of dialysis) rather than 
treatment with an aquaretic drug that has pre-
dictable, bothersome, long-term side effects. On 
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the other hand, patients at risk for rapid progres-
sion might prefer treatment with an aquaretic 
agent and choose to cope with the side effects. 
The development of comprehensive criteria for 
aquaretic treatment and appropriate patient selec-
tion are needed, if tolvaptan is to be a success-
ful therapy for patients with ADPKD.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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